Literature DB >> 18818868

Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab.

Patric Thierry Kurmann1, Daniel Van Linthoudt, Alexander Kai-Lik So.   

Abstract

Adalimumab is a frequently prescribed TNFalpha inhibitor for treatment of rheumatoid arthritis. We report on a patient who probably developed a Miller-Fisher syndrome after the second injection of adalimumab.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18818868     DOI： 10.1007/s10067-008-1017-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  4 in total

1.  An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia).

Authors:  M FISHER
Journal:  N Engl J Med       Date:  1956-07-12       Impact factor: 91.245

2.  Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

Authors:  B W van Oosten; F Barkhof; L Truyen; J B Boringa; F W Bertelsmann; B M von Blomberg; J N Woody; H P Hartung; C H Polman
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

3.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

Review 4.  Clinical and immunological spectrum of the Miller Fisher syndrome.

Authors:  Y L Lo
Journal:  Muscle Nerve       Date:  2007-11       Impact factor: 3.217
  4 in total
  3 in total

Review 1.  Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.

Authors:  Chandler Gill; Stasia Rouse; Ryan D Jacobson
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-17       Impact factor: 5.081

2.  Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors.

Authors:  Julius Birnbaum; Clifton O Bingham
Journal:  Semin Arthritis Rheum       Date:  2013-10-30       Impact factor: 5.532

Review 3.  Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review.

Authors:  Bonifacio Alvarez-Lario; Rosa Prieto-Tejedo; María Colazo-Burlato; Jesús Macarrón-Vicente
Journal:  Clin Rheumatol       Date:  2013-05-11       Impact factor: 2.980
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.